Maynard Um
-
-
-
-
-
-
-
CEL-SCI Corp (CVM) Offering 2M Shares at $2.50
-
-
-
-
-
-
-
CEL-SCI Corp's (CVM) Head and Neck Cancer Registration Study Protocol Clears FDA Review—in Talks with Potential Partners Interested in Commercialization of Multikine
-
-
-
-
-
-
-
CEL-SCI Corp (CVM): FDA’s ODAC Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine to Address Major Treatment Gap for PD-L1 Negative Cancer Patients
-
-
-
-
-
-
-
CEL-SCI Corp (CVM) Halted, News Pending
-
341,965 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

